Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population
| العنوان: | Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population |
|---|---|
| المؤلفون: | Andre B. Araujo, Sze-jung Wu, Kalyani Sonawane, Lawrence Chang, Joseph Singer, Natalie N. Boytsov, Ralph Quimbo, John T. Hinton, Cynthia Larmore, David M. Kern |
| المصدر: | Rheumatology and Therapy |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | musculoskeletal diseases, Health plan, medicine.medical_specialty, Practice patterns, Physicians’ rheumatoid, Population, Arthritis, Newly diagnosed, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Immunology and Allergy, 030212 general & internal medicine, Medical prescription, skin and connective tissue diseases, education, Medication adherence, Original Research, 030203 arthritis & rheumatology, education.field_of_study, business.industry, Guideline adherence, medicine.disease, Antirheumatic agents, Rheumatoid arthritis, Orthopedic surgery, business |
| الوصف: | Introduction To describe treatment patterns in newly diagnosed rheumatoid arthritis (RA) patients in a large, nationally representative managed-care database. Methods Newly diagnosed RA patients were identified from 07/01/2006–08/31/2014. Patients had ≥ 1 RA diagnosis by a rheumatologist, or ≥ 2 non-rheumatologist RA diagnoses ≥ 30 days apart, or RA diagnosis followed by a disease-modifying antirheumatic drug (DMARD) prescription fill within 1 year. Patients were ≥ 18 years old at index (earliest date fulfilling diagnostic criteria) and had ≥ 6 and 12 months of pre- and post-index health plan enrollment, respectively. Patterns of DMARD treatment, including conventional synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus kinase inhibitors (JAKi), were captured during follow-up. Results Of the 63,101 RA patients identified, 73% were female; mean age was 57 years. During an average of 3.5 ± 2.1 years of follow-up, 45% of patients never received a DMARD, 52% received a csDMARD (94 ± 298 mean ± SD days from index), 16% a TNFi (315 ± 448 days), 4% a non-TNFi (757 ± 660 days), and < 1% a JAKi. Among DMARD recipients, the most common treatment patterns were: receiving csDMARDs only (68%), adding a TNFi as second-line therapy after initiation of a csDMARD (12%), and receiving only a TNFi (6%) during follow-up. Among those not on DMARDs, the all-cause usage of an opioid was 56% and 19% had chronic opioid use (≥ 180 days supplied). Conclusions Despite American College of Rheumatology recommendations for DMARD treatment of RA, nearly half of newly diagnosed RA patients received no DMARD therapy during follow-up. These data identify a treatment gap in RA management. Funding Eli Lilly & Company. |
| تدمد: | 2198-6584 2198-6576 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec2e8b095fac7b9a99c6a7a97f3ca99 https://doi.org/10.1007/s40744-018-0114-6 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....1ec2e8b095fac7b9a99c6a7a97f3ca99 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 21986584 21986576 |
|---|